Filing Details
- Accession Number:
- 0001225208-22-003299
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-24 16:21:53
- Reporting Period:
- 2022-02-22
- Accepted Time:
- 2022-02-24 16:21:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
885725 | Boston Scientific Corp | BSX | Surgical & Medical Instruments & Apparatus (3841) | 042695240 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1529751 | A David Pierce | 300 Boston Scientific Way Marlborough MA 01752-1234 | Evp Pres Medsurg | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-02-22 | 1,884 | $42.55 | 1,761 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-02-23 | 1,761 | $43.28 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Performance Share Units | Acquisiton | 2022-02-22 | 17,439 | $0.00 | 17,439 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
17,439 | 2023-12-31 | 2023-12-31 | No | 4 | A | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
- Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023.